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Despite many advances in oncology, almost all patients with pancreatic cancer (PC) die of the disease. Molecularly targeted
agents are offering hope for their potential role in helping translate the improved activity of combination chemotherapy into
improved survival. Heat shock protein 27 (Hsp27) is a chaperone implicated in several pathological processes such as cancer.
Further, Hsp27 expression becomes highly upregulated in cancer cells after chemotherapy. Recently, a modiﬁed antisense
oligonucleotide that is complementary to Hsp27 (OGX-427) has been developed, which inhibits Hsp27 expression and enhances
drug efﬁcacy in cancer xenograft models. Phase II clinical trials using OGX-427 in different cancers like breast, ovarian, bladder,
prostate and lung are in progress in the United States and Canada. In this study, we demonstrate using TMA of 181 patients that
Hsp27 expression and phosphorylation levels increase in moderately differentiated tumors to become uniformly highly
expressed in metastatic samples. Using MiaPaCa-2 cells grown both in vitro and xenografted in mice, we demonstrate that OGX-
427 inhibits proliferation, induces apoptosis and also enhances gemcitabine chemosensitivity via a mechanism involving the
eukaryotic translation initiation factor 4E. Collectively, these ﬁndings suggest that the combination of Hsp27 knockdown with
OGX-427 and chemotherapeutic agents such as gemcitabine can be a novel strategy to inhibit the progression of pancreas
cancer.
Cell Death and Disease (2011) 2, e221; doi:10.1038/cddis.2011.104; published online 20 October 2011
Subject Category: Cancer
Pancreatic cancer (PC) remains one of the most deadly and
chemoresistant cancers. Multiple studies have evaluated
various chemotherapeutic agents, but a few have produced
signiﬁcantimprovementinsurvival.
1Gemcitabineremainsthe
ﬁrst-linedrugforthetreatmentofadvancedPC,eitheraloneor
incombinationwithotherchemotherapeuticagents.However,
the inherent resistance of PC to currently available che-
motherapeutic agents presents a major challenge.
1–3 Identi-
ﬁcation of robust new molecular target and relevant pathways
to restore sensitivity to chemotherapeutic agents is a top
priority.
1 Several mechanisms like STAT3, NF-kappaB and
others has been reported to induce gemcitabine resistance in
preclinical models.
4,5 However, in clinic, only one study
reportso2weeksofsurvivalimprovementwithacombination
of erlotinib and gemcitabine,
6 highlighting the urgent need to
ﬁnd novel agents against relevant molecular targets to make
new treatments.
Heat shock protein 27 (Hsp27) seems to have a crucial role
in regulating the balance between cell death and survival.
Hsp27 is phosphoactivated during cell stress to form
oligomers that prevent aggregation and/or regulate activity
and degradation of certain client proteins.
7 Hsp27 expression
is increased in a variety of malignancies including prostate
8,9
breast,
10 gastric,
11 ovarian,
12 bladder
13 and pancreas
cancer.
14 Furthermore, Hsp27 overexpression has been
associated with multi-drug resistance in several cancers
15
like prostate,
9 breast
16 and bladder.
17 Recently, Mori-Iwamo-
to et al.
18 demonstrated that Hsp27 is a biomarker of PC cell’s
resistance togemcitabine andits downregulationmediated by
interferon-gamma helps in cytotoxic effect of gemcitabine.
19
Antisense oligonucleotides (ASOs) are powerful tools that
speciﬁcally hybridize with complementary mRNA regions
forming RNA/DNA duplexes to inhibit target gene expression
in a sequence-speciﬁc manner. Several gene-targeting ASOs
in combination with other compounds, such as chemother-
apeuticagents,haveshownsynergisticanti-neoplasticeffects
in several tumor models. Recently, Hsp27 ASO and short
interference RNA (siRNA) were reported to potently inhibit
Hsp27 expression in human prostate PC-3 cells with
increased caspase-3 cleavage, apoptosis and 87% suppres-
sion of cell growth.
8,9,20 A second generation ASO-targeting
Hsp27 (OGX-427) is currently tested in phase II clinical trials
for prostate, bladder, ovarian, breast and lung cancers in the
United States and Canada.
21
In this study, we have been able to associate Hsp27
expression with bad prognosis in PC patients. Further, we
Received 01.6.11; revised 06.9.11; accepted 16.9.11; Edited by P Salomoni
1INSERM, U624 ‘Stress Cellulaire’, Parc Scientiﬁque et Technologique de Luminy, Marseille, France;
2Aix-Marseille Universite ´, Campus de Luminy, Marseille, France;
3The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada and
4INSERM, U866, Faculty of Medicine, Dijon, France
*Corresponding author: P Rocchi, INSERM, U624 ‘Stress Cellulaire’, Parc Scientiﬁque et Technologique de Luminy, 163 avenue de Luminy, 13289 Marseille, France.
Tel: þ33 491 828 808; Fax: þ33 491 826 083; E-mail: palma.rocchi@inserm.fr
Keywords: Hsp27; oligonucleotide antisense; pancreas cancer xenograft; eIF4E; gemcitabine chemoresistance
Abbreviations: ASO, antisense oligonucleotide; Hsp27, heat shock Protein 27; eIF4E, eukaryotic translation initiation factor 4E; TMA, tissue microarrays;
PC, pancreatic cancer; IPMNP, intraductal papillary mucinous neoplasms of the pancreas; EPT, endocrine pancreas; ADK, adenocarcinoma; WD, well-differentiated;
MD, moderately-differentiated; UD, undifferentiated; Meta, metastatic; TCL, total cell lysate; IP, immunoprecipitation; IB, immunoblotting
Citation: Cell Death and Disease (2011) 2, e221; doi:10.1038/cddis.2011.104
& 2011 Macmillan Publishers Limited All rights reserved 2041-4889/11
www.nature.com/cddishave explored the role of Hsp27 in PC cell survival
using MiaPaCa-2 cells grown both in vitro and in vivo, and
identiﬁed a function for Hsp27 in promoting cell growth and
chemoresistance.
Results
Hsp27 immunostaining increases in undifferentiated
and metastatic human PC. To study the role of Hsp27 in
PC, we determine its expression level by immunostaining in
181 pancreas cancer specimens spotted on a tissue
microarray (TMA). Hsp27 was found mostly in the
cytoplasm of epithelial cells of tumor glands (Figure 1a).
More speciﬁcally, while Hsp27 staining was absent or weak
in less aggressive tumors like intraductal papillary mucinous
neoplasms of the pancreas (IPMNP) and endocrine
pancreas tumors (EPT), it strongly increased with the loss
of differentiation in pancreas adenocarcinomas (ADK).
Further, pancreatic tumors from metastatic sites exhibited
uniform and highly positive Hsp27 staining in all specimens.
The mean intensity scored in percentage of numerous and
massive positive cells in IPMNP, EPT, well-differentiated
(WD) ADK, moderately/undifferentiated (MD/UD) ADK and
metastatic (Meta) samples were 42%, 43%, 68%, 71% and
90%, respectively (Figure 1b).
Overexpression of Hsp27 inhibits gemcitabine-induced
apoptosis and promotes tumor growth while Hsp27 down-
regulation has the opposite effects. In order to determine
whether Hsp27 overexpression could be part of PC cell’s
resistance to the ﬁrst-line chemotherapeutic agent gemcita-
bine, we established a MiaPaCa-2 cell line stably expressing
human Hsp27 cDNA (MiaPaCa-2-Hsp27). We ﬁrst conﬁrmed,
by western blot, elevated Hsp27 protein levels in MiaPaCa-2-
Hsp27 as compared with MiaPaCa-2 stably expressing the
empty vector (MiaPaCa-2-Mock) (Figure 2a). After 24h
treatment with gemcitabine (see Materials and Methods) cell
viability studies showed that MiaPaCa-2-Hsp27 cells were
more resistant to gemcitabine-induced apoptosis compared
with Mock cells (Figure 2b). Flow cytometry analysis revealed
that Hsp27 overexpression increased the resistance to
apoptosis induced by gemcitabine while decreasing the
percentage of cells in sub G0 phase (Figure 2c). Conversely,
OGX-427, an oligonucleotide antisense of second generation
speciﬁc for Hsp27 that induced a dose-dependent down-
regulation of Hsp27 (Figures 2d and e), inhibited cell growth
(Figure 2f), induced apoptosis (Figure 2g) and sensitized
MiaPaCa-2 cells to gemcitabine (Figure 2h).
OGX-427 inhibits proliferation and sensitizes to gemcita-
bine via inhibition of the eukaryotic translational initiation
factor 4E (eIF4E). We recently showed in prostate cancer
cells that a relevant pathway through which Hsp27 inhibits
apoptosis was by its interaction with eIF4E thereby protecting
this translational factor from its degradation.
22 We therefore
studied here the effect of OGX-427 treatment in eIF4E
stability. We found that in OGX-427-treated MiaPaCa-2 cells,
there was a decrease of B70% in eIF4E protein at 70nM
(Figures 3a and b). Consistent with this result, eIF4E content
was increased in MiaPaCa-2-Hsp27 compared with MiaPa-
Ca-2-Mock (Figure 3c). Hsp27 regulated eIF4E protein
expression, without affecting its mRNA expression (data not
shown) but by inducing a decrease of B30% in the amount of
ubiquitinated eIF4E (Figures 3d and e) thereby inhibiting its
proteasomal degradation as we already reported. As Hsp27
has been shown to induce resistance to cell death in other
cancer cell models by interacting with different cellular
partners
8,23 we studied the relevance of eIF4E in Hsp27-
induced resistance to gemcitabine in PC cells. We depleted
eIF4E by means of a speciﬁc siRNA
22 and studied the
protective effect of Hsp27. We found that when eIF4E was
depleted, Hsp27 was unable to modify the sensitivity of the
cells to gemcitabine, suggesting the relevance of Hsp27-
eIF4E association (Figure 3f).
Collectively, the results illustrated in Figure 3 and data
previously published by us indicates that Hsp27 levels
correlate with those of eIF4E.
22 Further, Hsp27 interacts
directly with eIF4E inhibiting its ubiquitination and proteaso-
mal degradation.
Hsp27 association with eIF4E involves its C-terminal
region and depends on the phosphorylation of the
chaperone. In order to analyze Hsp27-eIF4E interaction,
we used Hsp27 deletion mutants previously described by
Al-Madhoun et al.
24 The C-terminal mutant Hsp27 N1 (1-93)
lacks part of the a-crystallin domain, believed to mediate
oligomerization of Hsp27.
15 The Hsp27 N2 mutant (1–173)
lacks the ﬂexible domain (IXI box) at the C-terminal, believed
to be involved in the formation of multiple inter-subunit
interactions.
25 Finally, the N-terminal mutant, Hsp27 C1
(93–205), lacks the hydrophobic WDPF domain and the major
phosphorylation sites necessary for interacting with other
proteins and molecular chaperone function
26 (Figure 4a).
Immunoprecipitation of eIF4E followed by immunoblot
analysis with anti-histidine antibody was performed on
MiaPaCa-2 cells transiently transfected with constructs
carrying wild type (WT) and Hsp27 truncated mutant forms
(N1, N2 and C1). As shown in Figure 4b, eIF4E was able to
interact with WT-Hsp27 and N2, while hardly no or weak
interaction was observed with N1 and C1, respectively.
Interestingly, only transfection with N2 protected MiaPaCa-2
pancreatic cells to gemcitabine-induced apoptosis (protection
similar to that observed with WT-Hsp27). In contrast,
transfection with N1 or C1 sensitizes MiaPaCa-2 pancreatic
cells to gemcitabine (Figure 4c). These results suggest that
cytoprotectioninducedbyHsp27inMiaPaCa-2cellsseemsto
involve eIF4E interaction.
Phosphorylation of the 3 Serine (Ser) residues of Hsp27
(position 15, 78 and 82), has been shown to modulate Hsp27
functions.
7 To analyze the effect of Hsp27 phosphorylation on
its association with eIF4E, we used two phospho-mutants
(3D and 3A) of Hsp27 (Figure 5a). The 3D have the three Ser
residues replaced by aspartates that mimics the constitutively
phosphorylated protein. The 3A has the three Ser residues
replaced by alanines that mimic the constitutively depho-
sphorylated protein. We found that the constitutively phos-
phorylated 3D mutant bound to eIF4E more efﬁciently than
WT, while the non-phosphorylatable 3A mutant was unable to
do so (Figure 5b). Thus, Hsp27 phosphorylation considerably
increases eIF4E interaction.
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Cell Death and DiseasePhosphorylated Hsp27: a bad prognosis marker in
PC. Previous studies demonstrated that phosphorylation
levels of Hsp27 increased in advanced tumors and
correlate with treatment resistance.
23,27 Similarly, our
results shown above suggest that the phosphorylation of
Hsp27 (P-Hsp27) was necessary to confer resistance to
gemcitabine. This suggests that P-Hsp27 could be used as
bad prognosis factor in PC. To explore this hypothesis,
we checked Hsp27 phosphorylation status in human
TMA. Figure 6 illustrates that total- and P-Hsp27 are low in
WD ductal ADK, strongly increased with the loss of
differentiation to become uniformly highly positive in PC
from metastatic sites. The increased levels of P-Hsp27
correlated with total-Hsp27 and eIF4E. This result is
consistent with recent work published by Taba et al.
27
showing that Hsp27 is phosphorylated in gemcitabine-
resistant PC. Our results suggest that gemcitabine
resistance might involve eIF4E.
Figure 1 Changesin Hsp27 immunostaining in human pancreas cancer TMA. (ai and aii) IPMNP and EPT: a few foci of weakly positive cancer cells are visible, but most
tumor is not immunoreactive. (aiii, aiv and av) Strong immunoreactivity in WD, MD differentiated and UD ductal adenocarcinoma. (avi and avii) Sheets of uniformly and
intensivelyreactivetumor cells characteristic of liver and intraperitoneal Meta, respectively.(b) MeanHsp27 staining in humanPCTMA. Specimens spottedon the TMAwere
graded from negative, rare, numerous and massive representing the range of no staining to heavy staining by visual scoring and automated quantitative image analysis by
SAMBA ‘immune’ software. Data from 181 samples were used to calculate average ±S.E. All comparison of stain intensity was made at  200 magniﬁcation
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Cell Death and DiseaseAnti-cancer effect of OGX-427 in vivo. Male nude mice
bearing MiaPaCa-2 tumors were randomly selected for
treatment with OGX-427 or an ASO control administered
alone, or in combination with gemcitabine (see Materials and
Methods). Mean tumor volume was similar in all groups
before therapy (300–500mm
3 size). Figures 7a and b show
Figure 2 Effect of Hsp27 overexpression and downregulation on chemoresistant MiaPaCa-2 cells survival and apoptosis in vitro.( a) Western blot analysis of Hsp27 and
GAPDHprotein levelsinMiaPaCa-2cellsstablytransfectedwithemptyvector(MiaPaCa-2-Mock) orhumanHsp27(MiaPaCa-2-Hsp27).(b)MTTquantiﬁcation ofcellviability
of MiaPaCa-2-Hsp27 and -Mock cells and (c) apoptosis assay by ﬂow cytometry. The results are expressed in percentage to control (MiaPaCa-2-Mock). (d) Western blot
analysis of Hsp27 and GAPDH protein levels in MiaPaCa-2 cells transfected with OGX-427 as compared with MiaPaCa-2 ASO control. (e) Histograms of average
densitometries ofHsp27proteinlevelsafternormalizationtoGAPDHproteinlevelsbydensitometryanalysisin MiaPaCa-2 cellsaftertreatmentwith OGX-427orASOcontrol.
(f) MTT quantiﬁcation of cell viability of MiaPaCa-2 cells treated with OGX-427 or ASO control. (g) Flow cytometry quantiﬁcation of cell percentage in sub G0 phase of
MiaPaCa-2 cells treated with OGX-427 as compared with ASO control. (h) MTT quantiﬁcation of cell viability of MiaPaCa-2 treated with OGX-427 or ASO control combined
withdifferentconcentrationsofgemcitabine.ErrorbarsrepresentS.E.fromthreeindependentexperiments.Statisticalanalysisusedttest;*Pr0.05,**Pr0.01,***Pr0.001
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Cell Death and Diseasethat OGX-427 monotherapy signiﬁcantly reduced MiaPaCa-2
tumor volume by up to B50% from day 14 to 35 (*Pr0.05;
**Pr0.01). Moreover, treatment with OGX-427, compared
with ASO control, signiﬁcantly enhanced the apoptotic effect
of gemcitabine in vivo, reducing mean MiaPaCa-2 tumor
volume by B50%, 28 days after initiation of treatment
(**Pr0.01; Figures 7a and b). Under the experimental
conditions described above, no adverse effects were
observed. Microscopic studies in tumor slides conﬁrmed
that the anti-tumor effect of OGX-427 was associated with a
Figure3 Hsp27regulateseIF4Eandmediatescytoprotection.(a)WesternblotanalysisofHsp27,eIF4EandGAPDHproteinlevelsinMiaPaCa-2cellstreatedwithOGX-
427 or ASO control. (b) Histograms of average densitometries of eIF4E protein level after normalization to GAPDH protein level by densitometry analysis in MiaPaCa-2 cells
after treatment with OGX-427 or ASO control. (c) Western blot analysis of Hsp27, eIF4E and GAPDH protein levels in MiaPaCa-2 cells stably transfected with empty vector
(MiaPaCa-2-Mock) or human Hsp27 (MiaPaCa-2-Hsp27). (d) Western blot analysis of Hsp27, ubiquitin and eIF4E protein levels after eIF4E immunoprecipitation (IP) using
rabbit anti-eIF4E antibody (reIF4E) in MiaPaCa-2-Mock and MiaPaCa-2-Hsp27 cells. Total cell lysate (TCL) represents proteins from MiaPaCa-2-Mock vs MiaPaCa-2-Hsp27
cells, extracted from cultured cells and blotted as control with Hsp27 and GAPDH antibody. (e) Histograms of average densitometries of ubiquitine protein levels after
normalizationtoeIF4EproteinlevelsbydensitometryanalysisinMiaPaCa-2stablytransfectedwithHsp27orMockcontrol.(f)MTTquantiﬁcationofcellviabilityofMiaPaCa-2-
Mock and MiaPaCa-2-Hsp27 cells treated with 20nM control- or eIF4E-siRNA and gemcitabine (150mM). Error bars represent S.E. from three independent experiments.
Statistical analysis used t test; ***Pr0.001
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Cell Death and Diseasedecrease in Hsp27, eIF4E and ki67 proliferation index and an
increase in caspase-3-dependent apoptosis (Figure 7c).
Discussion
Hsp27 expression is induced by various stressors, such as
chemotherapy and can act at multiple control points in
apoptotic pathways to ensure that stress-induced damage
does not inappropriately trigger cell death.
28 Several mechan-
isms account for the cytoprotective effect of Hsp27, including:
(1) chaperone inhibitor of protein misfolding; (2) inhibition of
key effectors of the apoptotic machinery at the pre- and
post-mitochondrial level
8,20,29 and (3) proteasome-mediated
degradation of proteins under stress conditions.
28 Targeting
Hsp27 by the second generation ASO, OGX-427, inhibited
Hsp27 expression and enhanced drug sensitivity in several
xenograft models.
8,9,17 Although mechanisms by which
Hsp27 inhibits apoptosis are partially deﬁned, its role in PC
growth remains less clear.
Inthisstudy,weidentiﬁedusingTMAof181specimensthat
Hsp27 and P-Hsp27 are highly overexpressed in UD PC to
become uniformly and highly expressed in metastatic tumors.
The highly uniform expression of Hsp27 in metastatic lesions
further underscores the association of Hsp27 with the lethal
component of the disease. Recently, Mori-Iwamoto et al.
18
demonstrated that Hsp27 is a biomarker of resistance of PC
cells to gemcitabine and its downregulation mediated by
interferon-gamma contributes to gemcitabine cytotoxic
Figure 4 Hsp27 association with eIF4E involves its C-terminal region. (a) Schematic representation of Hsp27 structure and deletion mutants used in this study. (b)
WesternblotanalysisofhistidineandeIF4EproteinlevelsaftereIF4Eimmunoprecipitation(IP)usingrabbitanti-eIF4Eantibody(reIF4E)orrabbitIgGascontrolinMiaPaCa-2
cells transiently transfected with WT Hsp27 or truncated mutant forms (N1, N2 and C1) of Hsp27. In the lower panel, western blot analysis of histidine and vinculin levels from
total protein extracts (TCL). (c) MTT quantiﬁcation of cell viability of MiaPaCa-2 cells transiently transfected or not with Hsp27 deletion mutants and treated with gemcitabine
(150mM). Error bars, S.E. from three independent experiments. Statistical analysis used t test; ***Pr0.001
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Cell Death and Diseaseeffect.
19 We extend these observations in this work showing
that increased Hsp27 levels confer antiapoptotic advantage
enhancing gemcitabine apoptosis in chemoresistant MiaPa-
Ca-2 model. Knockdown of Hsp27 in MiaPaCa-2 cells using
OGX-427 inhibits proliferation and induces apoptosis in vitro
and in vivo. Furthermore, additive effect was observed when
MiaPaCa-2 cells or xenografts were treated with OGX-427
plus gemcitabine.
The mammalian target of rapamycin (mTOR) pathway
(eIF4E), has been described to regulate cell survival, and was
recently recognized as therapeutic target in several cancers
30
including PC.
31 In most systems, cap-dependent translation
depends on eIF4E levels and eIF4E can exert oncogenic
effects when overexpressed.
32,33 Previous studies have
shown that the mTOR pathway is constitutively active in
serum-starved MiaPaCa-2 cells
34 and that eIF4E is upregu-
lated in PC compared with normal cells.
31 Recently, we found
that Hsp27 affects eIF4E stability, mediating chemoresis-
tance of advanced prostate cancer.
22 In this report, we
demonstrate in MiaPaCa-2 model that changes in Hsp27
expression serve as an upstream regulator of eIF4E. More-
over, we show that Hsp27 and P-Hsp27 levels are directly
correlated with eIF4E.
In spite of the importance of eIF4E, little is known about its
regulation and role in PC chemoresistance. Transcription of
eIF4E gene is induced in response to many stimuli including
serum and growth factors.
35 However, mechanisms regulat-
ingeIF4Eproteinexpressionremainundeﬁned.Othumpangat
et al.
36 recently reported that eIF4E is ubiquitinated and
degraded in a proteasome-dependent manner. Ubiquitin is a
low-molecular-weight polypeptide covalently conjugated to
lysine residues in target proteins that serve as signal for
delivery to and proteolysis by the proteasome.
37 The
ubiquitin–proteasome pathway is an important factor control-
ling the expression and activity of regulatory proteins, such as
transcriptionfactors,cell cycleregulatorsandsignaltransduc-
tion proteins.
38 We recently showed in prostate cancer model
that the ubiquitin–proteasome pathway regulates the turnover
of eIF4E and cell proliferation. We reported that eIF4E
complexes with Hsp27 that induced androgen withdrawal
and paclitaxel chemoresistance.
22 Here we demonstrated
Hsp27-eIF4E interaction contributes to the overall gemcita-
bine resistance in MiaPaCa-2 cells and this interaction is
favored by phosphorylation of Hsp27.
In summary, the results of this study support the hypothesis
that increased Hsp27 in UD and metastatic PC is an adaptive
response enhancing cell survival. Hsp27 silencing using
OGX-427 alters eIF4E signaling, enhances apoptosis,
potentiates gemcitabine activity and offers a new treatment
strategy to delay progression of PC. These results provide
preclinical proof of principle for the use of OGX-427 asa novel
therapeutic strategy in the treatment of PC.
Materials and Methods
Pancreas tissue specimens. Archival resection specimens from 181
patients were studied. Tissue fragments were processed in the Pathology
Department,Ho ˆpitalNord(SG).AllsamplesusedforTMAconstructionwereﬁxedin
buffered formalin and parafﬁn embedded. Differentiation and pathological staging
were assessed by histological examination according to criteria deﬁned by Kloppel
et al.
39 Histopathological diagnoses were: IPMNP (n¼13), EPT (n¼24), ductal
ADK ((WD; n¼65), (MD; n¼12) and (UD; n¼21)) and Meta of pancreatic ductal
ADK (peritoneal n¼25, liver n¼21).
TMA analysis. TMA were prepared as previously described.
40 For each tumor,
two representative tumor areas were delineated by circling within tissue sections
appropriate areas with a permanent black pen on hematoxylin- and eosin-stained
parafﬁn sections to guide the punches of cores. Cores were sampled using the
ALPHELYS Arraying Device (ALPHELYS, Plaisir, France). Core cylinders of
0.6mm diameter, punched from the donor block, were then deposited in the
recipient parafﬁn block. TMA sections (4mm thick) were cut 24h before
immunohistochemical (IHC) processing.
Immunostaining. The IHC procedure was performed with a Ventana
Benchmark autostainer (Ventana, Illkirch, France) using the manufacturer
procedure and kit as previously reported.
40 Slides were incubated for 32min at
371C with speciﬁc antibodies from Nova Castra (Newcastle, UK) for total Hsp27,
stressgen for the phospho Hsp27 (P-Hsp27) and Cell Signaling technology, Inc.
(Danvers, MA, USA) for eIF4E at the concentration of 1/100 in 1% BSA primary
antibodies.
Scoring of Hsp27 staining. TMA analysis using the SAMBA 2050
automated device (TRIBVN/SAMBA Technologies, Chatillon, France) was
performed according to the protocol previously described.
40 SAMBA ‘immuno’
software was applied. Several parameters per core were computed: the area of
counterstaining, the ratio (as percentage) of the positive area vs counterstained
areas and a quick score (percentage of positive area mean optical density (OD)).
OD was evaluated on a scale of grey levels (arbitrary units) ranging from 0 to 255.
The computation of each parameter obtained provided numerical values consisting
of continuous variables for statistical tests.
Figure 5 Hsp27-eIF4E interaction depends on Hsp27 phosphorylation.
(a) Schematic representation of WT and phosphorylation mutants (3D and 3A) of
Hsp27 used in this study. (b) Western blot analysis of histidine and eIF4E protein
levels after eIF4E immunoprecipitation (IP) using rabbit anti-eIF4E antibody
(reIF4E) in MiaPaCa-2 cells transiently transfected with Hsp27 WT or 3D
(constitutively phosphorylated) and 3A (constitutively dephosphorylated) vectors. In
the lower panel, western blot analysis of histidine and vinculin levels from total
protein extracts (TCL)
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Cell Death and DiseaseTumor cell line. The human chemoresistant PC cell line MiaPaCa-2 obtained
from the American Type Culture Collection was maintained in Dulbecco’s Modiﬁed
Eagle Medium (DMEM, Life Technologies, Inc., Gaithersburg, MD, USA)
supplemented with 10% fetal calf serum. Cells were routinely grown in 50ml
ﬂasks at 371C in a humidiﬁed 5% CO2–95% air atmosphere.
Lentiviral Infection of MiaPaCa-2 cells with Hsp27. The full-length cDNA for
human Hsp27 was sub cloned into the lentiviral vector pHR’-CMV-EGFP at the
BamHI and XhoI sites. Two vectors were created for this study: pHR’-CMV-Hsp27
(Hsp27) and pHR’-CMV (Mock) as previously described.
8
Chemotherapeutic agent. Gemcitabine (Gemzar, Lilly Pharmaceutical
Company, Suresnes, France) was kindly provided by Dr. Muracciole X (Timone
Hospital, Marseilles, France).
Figure6 TotalHsp27,phospho-Hsp27andeIF4ElevelsinPCtumors.ImmunohistochemistryanalysisforHsp27,P-Hsp27andeIF4Einhumanpancreascancertumors.
Specimensfromwell-differentiated,moderately-differentiated,undifferentiatedADKandmetastasis(liver,intraperitoneal)werestainedwithphospho-serine-15(P-Ser15),-78
(P-Ser 78) and -82 (P-Ser 82) Hsp27, total Hsp27 or eIF4E in back to back sections
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Cell Death and DiseaseASO and siRNA sequences and treatment. Hsp27 ASO sequences
were manufactured by ISIS Pharmaceuticals (Carlsbad, CA, USA) and supplied by
OncoGenex Technologies (Vancouver, British Columbia, Canada) as previously
described.
17 The eIF4E siRNA was the Hs_eIF4E_1_HP validated siRNA from
Qiagen (Courtaboeuf, France). The control siRNA was from the same source.
Plated cells were treated with indicated siRNA or ASO concentrations according to
the protocol previously described.
22
Hsp27 deletion and phosphorylation mutant’s transfec-
tion. Histidine-tagged (His-tag) Hsp27 WT and three deletion mutants (N1, N2
and C1) in pcDNA4 containing His-tag epitope at N-terminal of the inserted
fragment
24 were kindly provided by Pr O’Brien (Ottawa University, Ontario,
Canada).The phosphorylationmutants (3D and 3A)in pDEST26(Invitrogen,Cergy
Pontoise, France) containing His-tag at N-terminal of the inserted fragment were
obtainedafteragatewayrecombinationwiththephosphorylationmutantsinpENTR
kindly provided by Dr. William Gerthoffer (University of South Alabama, USA).
MiaPaCa-2 cells were transfected with 10mg WT, deletion or phosphorylation
mutants using Fugene reagent (Roche Diagnostics GmbH, Mannheim, Germany)
according to the manufacturer’s instructions. Cleared lysates were obtained 48h
post transfection according to our previous experiments.
9
In vitro mitogenic assay. The in vitro growth effects were assessed in 12-well
microtiter plates using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay as previously described.
9 MiaPaCa-2-Mock and -Hsp27 cells
weretreatedwith150mMgemcitabine,andMTTassayswereperformedafter24h.
Wild-type MiaPaCa-2 cells were treated once daily with 70nM OGX-427 for 2 days
and MTT assays were performed 72h after OGX-427 treatment. MiaPaCa-2 cells,
transiently transfected or not with Hsp27 deletion mutants, were treated with
gemcitabine during 48h after transfection and cell viability was assayed 72h later.
Flow cytometryanalysis. Flow cytometry of propidium iodide-stained nuclei
wasperformedasdescribedpreviously.
9Brieﬂy,MiaPaCa-2-Mockand-Hsp27cells
were treated with 150mM gemcitabine. After 24h, cells were analyzed for relative
DNAcontentonaduallaserﬂowcytometer(BeckmanCoulterEpicsElite,Beckman
Inc., Miami, FL, USA). MiaPaCa-2 cells were treated once daily with OGX-427 for 2
days, and ﬂow cytometry assays were performed 24h after OGX-427 treatment.
Western blot analysis. Western blot analysis was performed as described
previously
9using1:5000rabbitanti-Hsp27polyclonalantibody(Assaydesigns,MI,
USA), 1:1000 mouse anti-Hsp27 monoclonal antibody (Assay designs), 1:1000
rabbit anti-eIF4E polyclonal antibody (Cell Signaling technology, Inc.), 1:500
mouse anti-ubiquitin monoclonal antibody (Santa Cruz Biotechnology, Inc.,
Delaware, CA, USA) and 1:3000 mouse monoclonal histidine antibody (Sigma,
St. Louis, MO, USA). Loading levels were normalized using 1:5000 rabbit anti-
GAPDH polyclonal antibody or 1:2500 mouse anti-vinculin monoclonal antibody
(Sigma).
Immunoprecipitation. Cleared lysates with adjusted protein concentration
(Protein assay, BioRad, Marnes-la-Coquette, France) were used for
immunoprecipitation with rabbit anti-Hsp27 antibody (Assay designs), rabbit anti-
eIF4Eantibody(CellSignalingtechnology,Inc.),rabbitIgG(rIgG;Millipore,Billerica,
MA, USA) at 41C. Immune complexes were precipitated following 1-h incubation
with 30ml true blot rabbit beads (eBiosciences SAS, Paris, France) at 41C.
Complexes were suspended in protein sample buffer (BioRad) and boiled for 5min.
Figure 7 Anti-cancer effect of OGX-427 on MiaPaCa-2 tumor growth and gemcitabine sensitivity in vivo.( a) and (b) MiaPaCa-2 tumor volume measurement
(length width depth 0.5236) in 40 nude randomly selected for treatment with OGX-427 or ASO control. When MiaPaCa-2 tumors reached 300–500mm
3, OGX-427 or
ASO control were injected i.p. for 5 weeks for OGX-427 (a and b) (see Materials and Methods section). Points represent mean tumor volume in each experimental
group containing 10 mice; Error bars represent S.E. Statistical analysis used t test; *Pr0.05, **Pr0.01. (c) IHC staining of MiaPaCa-2 tumor xenografts. Tumors were
resected and processed for histological analysis as previously described in Materials and Methods sections. Tissue sections were stained with antibodies to ki67 and cleaved
caspase-3
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Cell Death and DiseaseWestern Blot analysis was performed as previously described
9 with secondary anti-
mouse and anti-rabbit true blot HRP-conjugated antibodies (eBiosciences).
Assessment of in vivo tumor growth. For in vivo study, 10
6 MiaPaCa-2
cells were inoculated s.c. with 0.1ml of Matrigel (Becton Dickinson Labware,
Franklin Lakes, NJ, USA) in the ﬂank region of 4–5 week-old male athymic
nude mice (Harlan Sprague Dawley, Inc. Indianapolis, IN) via 27-gauge needle.
Tumors were measured weekly and their volumes were calculated by the
formula length width depth 0.5236. When MiaPaCa-2 tumors reached
300–500mm
3, mice were randomly selected for treatment with OGX-427 alone,
ASOcontrolalone,OGX-427andASOcontrolplusgemcitabine.Eachexperimental
groupconsistedof10mice.Afterrandomization,10mg/kgOGX-427orASOcontrol
was injected i.p. three times a week for 5 weeks. A total of 150mg/kg gemcitabine
was administrated i.v. every 3 days from day 7 to 14 and from day 21 to 28. Data
points were expressed as average tumor volume levels ±S.E.
Immunohistochemical determination of Ki67 and caspase-3 for
proliferation index and in situ apoptosis. The expression of Ki67 and
caspase-3 was detected in histological sections of tumor xenografts. Sections were
cut from formalin-ﬁxed and parafﬁn-embedded tissue blocks. The primary rabbit
monoclonal anti-ki67 (1/200) and caspase-3 (1/50) antibodies from Epitomic, Inc.
(Burlingame, CA, USA) was added. The sections were incubated with
diaminobenzidine substrate as chromogen.
Statisticalanalysis. Alltheresultswereexpressedasmean±S.E.Statistical
analysis was performed by one-way ANOVA followed by Fisher’s protected least
signiﬁcant difference test (Statview 512, Brain Power Inc., Calabases, CA, USA).
Pr0.05 was considered signiﬁcant (*); Pr0.01 (**); Pr0.001 (***).
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